<code id='5B1562CB76'></code><style id='5B1562CB76'></style>
    • <acronym id='5B1562CB76'></acronym>
      <center id='5B1562CB76'><center id='5B1562CB76'><tfoot id='5B1562CB76'></tfoot></center><abbr id='5B1562CB76'><dir id='5B1562CB76'><tfoot id='5B1562CB76'></tfoot><noframes id='5B1562CB76'>

    • <optgroup id='5B1562CB76'><strike id='5B1562CB76'><sup id='5B1562CB76'></sup></strike><code id='5B1562CB76'></code></optgroup>
        1. <b id='5B1562CB76'><label id='5B1562CB76'><select id='5B1562CB76'><dt id='5B1562CB76'><span id='5B1562CB76'></span></dt></select></label></b><u id='5B1562CB76'></u>
          <i id='5B1562CB76'><strike id='5B1562CB76'><tt id='5B1562CB76'><pre id='5B1562CB76'></pre></tt></strike></i>

          
          WSS
          Roche HQ
          SEBASTIEN BOZON/AFP via Getty Images

          The multibillion-dollar hunt for what many drugmakers hope will be the next big immunotherapy target has had no shortage of twists and tea-leaf-reading. In the wee hours of Wednesday morning, it got another.

          Roche confirmed it accidentally released interim data from a closely watched clinical trial testing whether blocking that target — a protein on T cells known as TIGIT — can enable non-small lung cancer patients to live longer than standard immunotherapy alone.

          advertisement

          The announcement release came hours after Evercore analyst Umer Raffat emailed investors that he had found a presentation on a Roche media portal, presumably uploaded by accident.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          comprehensive